regulatory status is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-26. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
CPC Scientific Group was founded in 2001, and the US company established in 2005 by Shawn Lee, Ph.D., and began by supplying research-grade custom peptides, catalog peptides, and Fmoc-protected amino acids. In 2006, the company opened a GMP (Good Manufacturing Practice) facility in Hangzhou, China to support the production of peptides for clinical use. The Hangzhou site underwent its first inspection by the U.S. Food and Drug Administration (FDA) in 2011, after which CPC Scientific began supplying pharmaceutical-grade peptides to clients in the United States. On March 17, 2016, the company passed a fourth FDA inspection. In 2024, the company completed a fifth U.S. FDA inspection and was also inspected by Australia’s Therapeutic Goods Administration (TGA). In 2025, CPC Scientific obtained ISO 22716:2007 Cosmetic GMP certification for the manufacture of peptide ingredients for cosmetic applications. CPC Scientific is part of Medtide Inc., which was listed on the Main Board of the Hong Kong Stock Exchange on June 30, 2025 (Stock Code: 03880).
=== Modern reception === Bloodlines is considered a cult classic. Retrospective critiques continue to praise the game's narrative and degree of choice. In 2009, an article in Rock, Paper, Shotgun declared: "The sense of sorrow comes from the realization that there's nothing like [Bloodlines] on the horizon ... why should there be so few games like this? Oh right, because it's so very hard to do ... the lack of games comparable to Bloodlines is one of the great tragedies of our time." Eurogamer called the game inspirational, with an unmatched level of narrative detail. In 2010, The Escapist called Bloodlines a flawed masterpiece which could have been a genuine masterpiece with more time, money, and staff; although great games may inspire awe, it instead created a devoted fan base which continued to develop the game. In 2006, PC Zone listed Bloodlines the seventh-best PC game which people were unlikely to have played, calling it the "best buggy game ever released". In 2007, the game was 80th on Computer & Video Games' list of its top 100 games, and 86th on PC Gamer's 2014 list of the same; it also appeared in PC Gamer's 2015 edition (moving to 63rd), 2017 edition (moving to 42nd), and 2021 edition (moving to 93rd). In 2008, bit-tech listed Jeanette as the second-best non-player video game character. In 2011, Rock, Paper, Shotgun called Bloodlines one of the most important PC games of all time ("it signposts a direction to a future of games that we were denied"), listing it as one of the 122 Best PC Games Ever.
Cmax: Maximum serum concentration that the drug achieves in the body after the drug has been administered tmax: Time to achieve maximum plasma concentration t1/2: Biological half-life In studies that were made on healthy people and people with type 2 diabetes, who were given dapagliflozin in either single ascending dose (SAD) or multiple ascending dose (MAD) showed results that confirmed a pharmacokinetic profile of the medication. With dose-dependent concentrations the half-life is about 12–13 hours, Tmax 1–2 hours and it is protein-bound, so the medication has a rapid absorption and minimal excretion by the kidney. Dapagliflozin disposition is not evidently affected by body mass index (BMI) or body weight, therefore, the pharmacokinetic findings are expected to be applicable to patients with a higher BMI. Dapagliflozin resulted in dose-dependent increases excretions in urinary glucose, up to 47g/d following single-dose administration, which can be expected from its mechanism of action. Some studies found that dapagliflozin is associated with a decrease in body weight, which is statistically superior compared to placebo or other active comparators. It is primarily associated with caloric rather than fluid loss. In contrast with other anti-hyperglycemic diabetes medications, SGLT2 inhibitors enhance, rather than suppress, gluconeogenesis and ketogenesis. Because SGLT2 inhibitors activate sirtuin 1 (and thus PGC-1α and FGF21), they are more cardioprotective than the other medications used to treat diabetes.
Sources: en.wikipedia.org
== Product life cycle approach in validation == Validation process efforts must account for the complete product life cycle, including developmental procedures adapted for qualification of a drug product commencing with its research and development phase, rationale for adapting a best fit formula which represents the relationship between required outputs and specified inputs, and procedure for manufacturing. Each step is required to be justified and monitored in order to provide a good quality food and drug product. The FDA emphasizes the product life cycle approach in its evaluation of manufacturer regulatory compliance as well.
Pickled tofu (豆腐乳 in Chinese, pinyin: dòufurǔ, or 腐乳 fŭrŭ; chao in Vietnamese), also called "preserved tofu" or "fermented tofu", consists of cubes of dried tofu that have been allowed to fully air dry under hay and slowly ferment with the help of aerial bacteria. The dry fermented tofu is then soaked in salt water, Chinese rice wine, vinegar or minced chili peppers, or in a mixture of whole rice, bean paste, and soybeans. In the case of red pickled tofu (紅豆腐乳 in Chinese, Pinyin: hóng dòufurǔ), red yeast rice (cultivated with Monascus purpureus) is added for color. In Japan, pickled tofu with miso paste is called tofu no misodzuke, and is a traditional preserved food in Kumamoto. In the Ryukyu Islands, pickled and fermented tofu is called tōfuyō (豆腐餻). It is made from Shima-dōfu (an Okinawan variety of large and firm tofu). It is fermented and matured with koji mold, red koji mold, and awamori. Stinky tofu (臭豆腐 in Chinese, Pinyin: chòudòufu) is soft tofu that has been fermented in a vegetable and fish brine. The blocks of tofu have a pungent cheese smell, sometimes resembling rotting food. Despite its strong odor, the flavor and texture of stinky tofu is appreciated by aficionados, who describe it as delightful. The texture of this tofu is similar to the soft East Asian tofu from which it is made. The rind that stinky tofu develops when fried is said to be best when especially crisp, and fried stinky tofu is usually served with soy sauce, sweet sauce, or hot sauce.
He had to leave the game after the seventh with a pulled back muscle, but he was back in action four days later. He won just twice more all season, as he dealt with back problems. On August 1, he again struck out eight Phillies but received a no decision, as he was removed with one out in the ninth and the game tied 1–1. The Cardinals won on a Stan Musial home run in the bottom of the inning. In 31 games (30 starts), he had a 13–10 record, a 4.20 ERA, 108 strikeouts, and 89 walks in 201+1⁄3 innings pitched. By 1960, Mizell had recovered from his back issues. He began the season with the Cardinals but only won one of his first nine games, posting a 4.55 ERA. By this point, the Cardinals felt that he had never attained his full potential. On May 28, they traded him and Dick Gray to the Pirates for Ed Bauta and Julián Javier, the latter of whom would reach two All-Star Games and win two World Series with the Cardinals over the next decade.
stringency The effect of conditions such as temperature and pH upon the degree of complementarity that is required for a hybridization reaction to occur between two single-stranded nucleic acid molecules. In the most stringent conditions, only exact complements can successfully hybridize; as stringency decreases, an increasing number of mismatches can be tolerated between the two hybridizing strands.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.